These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1343266)

  • 1. Hemodynamic profiles of antihypertensive agents.
    Lund-Johansen P
    Blood Press Suppl; 1992; 1():16-22; discussion 23. PubMed ID: 1343266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between cardiovascular haemodynamics and goals of antihypertensive therapy.
    Lund-Johansen P
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S21-8. PubMed ID: 8487246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential hypertension: hemodynamic and therapeutic changes over 20 years.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S1-7. PubMed ID: 1721971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of calcium antagonist, angiotensin-converting enzyme inhibitors and beta-blocker on hemodynamic and sympathetic nerve responses to exercise in essential hypertension].
    Fujiwara S; Arita M; Ueno Y; Shiotani M; Nakatsu C; Nakamura Y; Hano T; Nishio I; Masuyama Y
    J Cardiol; 1991; 21(1):115-24. PubMed ID: 1687786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age hemodynamics and exercise in essential hypertension: difference between beta-blockers and dihydropyridine calcium antagonists.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1989; 14 Suppl 10():S7-13. PubMed ID: 2483573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the hemodynamic effects of five calcium channel blockers at rest and during exercise in essential hypertension.
    Omvik P; Lund-Johansen P
    Ann Clin Res; 1988; 20 Suppl 48():23-30. PubMed ID: 3250315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cardiac effects of hypotensive agents in normotensive mature rats: comparison of beta-blocking agent and converting enzyme inhibition.
    Azizi M; Levy B; Salzmann JL; Cerol ML; Poitevin P; Ménard J; Michel JB
    J Cardiovasc Pharmacol; 1989 May; 13(5):691-701. PubMed ID: 2472516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
    Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
    Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antihypertensive therapy on the hemodynamics of hypertension: clinical implications.
    Lund-Johansen P
    Clin Ther; 1986; 8(4):382-97. PubMed ID: 3524841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nisoldipine. Central haemodynamics at rest and during exercise in essential hypertension: acute and chronic studies.
    Omvik P; Lund-Johansen P; Haugland H
    J Hypertens; 1988 Feb; 6(2):95-103. PubMed ID: 3351300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamics and exercise tolerance after bisoprolol, nifedipine, and their combination in patients with angina pectoris.
    Schnellbacher K; Bestehorn HP; Roskamm H
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S201-7. PubMed ID: 11527130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central hemodynamic effects at rest and during exercise of acute and chronic treatment with nisoldipine in essential hypertension.
    Omvik P; Lund-Johansen P; Haugland H
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S182-4. PubMed ID: 2455128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ACE inhibitors and their clinical significance].
    Brunner HR; Waeber B; Nussberger J
    Herz; 1987 Dec; 12 Suppl 1():3-9. PubMed ID: 3325394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The case for beta-blockers as first-line antihypertensive therapy.
    Cruickshank JM
    J Hypertens Suppl; 1992 Jun; 10(3):S21-7. PubMed ID: 1353111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension].
    Klaus D
    Z Kardiol; 1988; 77 Suppl 3():73-88. PubMed ID: 3062960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antihypertensive medications on exercise performance: a review.
    Chick TW; Halperin AK; Gacek EM
    Med Sci Sports Exerc; 1988 Oct; 20(5):447-54. PubMed ID: 2904108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension.
    Nannan ME; Melin JA; Vanbutsele RJ; Lavenne F; Detry JM
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1043-8. PubMed ID: 6085364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.